Clinical Trial Update: Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA)

View source ↗

Summary

A clinical trial investigating early diagnosis of Parkinson's disease by detecting alpha-synuclein aggregates using PMCA has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Snippet

Sponsor: Huashan Hospital | Conditions: Parkinson's Disease | Status: WITHDRAWN